BR0014041A - Use of csaids in rhinovirus infection - Google Patents

Use of csaids in rhinovirus infection

Info

Publication number
BR0014041A
BR0014041A BR0014041-4A BR0014041A BR0014041A BR 0014041 A BR0014041 A BR 0014041A BR 0014041 A BR0014041 A BR 0014041A BR 0014041 A BR0014041 A BR 0014041A
Authority
BR
Brazil
Prior art keywords
csaids
rhinovirus infection
infection
symptoms
rinovirus
Prior art date
Application number
BR0014041-4A
Other languages
Portuguese (pt)
Inventor
Susan B Dillon
Sandra D Griego
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of BR0014041A publication Critical patent/BR0014041A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Abstract

"UTILIZAçãO DE CSAIDS EM INFECçãO POR RINOVìRUS". A presente invenção está direcionada para o novo uso de um inibidor de CSBP/p38 para o tratamento de sintomas do resfriado comum e da exacerbação de sintomas associados com isso em humanos."USE OF CSAIDS IN RINOVIRUS INFECTION". The present invention is directed to the novel use of a CSBP / p38 inhibitor for the treatment of common cold symptoms and associated exacerbation of symptoms in humans.

BR0014041-4A 1999-09-17 2000-09-15 Use of csaids in rhinovirus infection BR0014041A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15449499P 1999-09-17 1999-09-17
PCT/US2000/025386 WO2001019322A2 (en) 1999-09-17 2000-09-15 Use of csaids in rhinovirus infection

Publications (1)

Publication Number Publication Date
BR0014041A true BR0014041A (en) 2003-07-15

Family

ID=22551566

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0014041-4A BR0014041A (en) 1999-09-17 2000-09-15 Use of csaids in rhinovirus infection

Country Status (17)

Country Link
EP (1) EP1223924A4 (en)
JP (1) JP2003516314A (en)
KR (1) KR20020032591A (en)
CN (1) CN1382044A (en)
AR (1) AR025691A1 (en)
AU (1) AU7584500A (en)
BR (1) BR0014041A (en)
CA (1) CA2385722A1 (en)
CO (1) CO5200855A1 (en)
CZ (1) CZ2002939A3 (en)
HU (1) HUP0204333A3 (en)
IL (1) IL148329A0 (en)
NO (1) NO20021301L (en)
PL (1) PL363116A1 (en)
TR (1) TR200200673T2 (en)
WO (1) WO2001019322A2 (en)
ZA (1) ZA200202060B (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
EP1337255A4 (en) * 2000-10-19 2006-01-25 Smithkline Beecham Corp Use of p38 inhibitors for the treatment of inflammation-enhanced cough
HU229471B1 (en) 2000-10-23 2014-01-28 Smithkline Beecham Corp 2,4,8-trisubstituted-8h-pyrido[2,3d]pyrimidine-7-one compounds, for the treatment of diseases mediated by csbp/p38 kinase
ATE385777T1 (en) * 2002-03-20 2008-03-15 Elan Pharma Int Ltd NANOPARTICLE COMPOSITIONS OF MITOGEN-ACTIVATED PROTEIN (MAP) KINASE INHIBITORS
MXPA04009605A (en) * 2002-04-05 2005-01-11 Boehringer Ingelheim Pharma Method of treating mucus hypersecretion.
AU2003245989A1 (en) * 2002-07-09 2004-01-23 Boehringer Ingelheim Pharma Gmbh And Co. Kg Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
JP4593953B2 (en) * 2004-03-30 2010-12-08 杏林製薬株式会社 Rhinovirus infection prophylaxis
MX2007001561A (en) * 2004-08-04 2007-04-16 Schering Corp Pharmaceutical formulations comprising pleconaril for the treatment of airway diseases.
PE20100737A1 (en) 2005-03-25 2010-11-27 Glaxo Group Ltd NEW COMPOUNDS
ES2436037T3 (en) * 2008-03-20 2013-12-26 Krister Tano Nasal spray or nasal drops for the treatment of the common cold
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
CN102573886A (en) * 2009-09-17 2012-07-11 相互制药公司 Method of treating asthma with antiviral agents
GB201010193D0 (en) 2010-06-17 2010-07-21 Respivert Ltd Medicinal use
GB201010196D0 (en) * 2010-06-17 2010-07-21 Respivert Ltd Methods
US11730760B2 (en) 2011-04-01 2023-08-22 The Bioregentech Institute, Inc. Laser assisted wound healing protocol and system
US11389663B2 (en) 2011-04-01 2022-07-19 Bioregentech, Inc. Laser assisted wound healing protocol and system
GB201611712D0 (en) 2016-07-02 2016-08-17 Hvivo Services Ltd Methods and compounds for the treatment or prevention of severe or persistent influenza
PT3691620T (en) 2017-10-05 2022-10-06 Fulcrum Therapeutics Inc P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
GB201721793D0 (en) 2017-12-22 2018-02-07 Hvivo Services Ltd Methods and compunds for the treatment or prevention of hypercytokinemia and severe influenza
WO2021216754A1 (en) * 2020-04-21 2021-10-28 Spring Discovery, Inc. Use of p38 mapk inhibitors for prevention and treatment of aging and aging-related disorders and for boosting an immune system

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3927216A (en) * 1971-06-01 1975-12-16 Icn Pharmaceuticals 1,2,4-Triazol E-3-carboxamides for inhibiting virus infections
US3984396A (en) * 1971-06-01 1976-10-05 Icn Pharmaceuticals, Inc. 1-(β,-D-ribofuranosyl)-1,2,4-triazole acid esters
US5656644A (en) * 1994-07-20 1997-08-12 Smithkline Beecham Corporation Pyridyl imidazoles
US5658903A (en) * 1995-06-07 1997-08-19 Smithkline Beecham Corporation Imidazole compounds, compositions and use
AP9700912A0 (en) * 1996-01-11 1997-01-31 Smithkline Beecham Corp Novel cycloalkyl substituted imidazoles
US6469018B1 (en) * 1999-01-08 2002-10-22 Smithkline Beecham Corporation Compounds

Also Published As

Publication number Publication date
CN1382044A (en) 2002-11-27
WO2001019322A2 (en) 2001-03-22
HUP0204333A3 (en) 2004-07-28
PL363116A1 (en) 2004-11-15
NO20021301L (en) 2002-05-16
CZ2002939A3 (en) 2002-11-13
EP1223924A4 (en) 2004-07-14
HUP0204333A2 (en) 2003-05-28
AU7584500A (en) 2001-04-17
TR200200673T2 (en) 2002-12-23
EP1223924A2 (en) 2002-07-24
JP2003516314A (en) 2003-05-13
AR025691A1 (en) 2002-12-11
CA2385722A1 (en) 2001-03-22
CO5200855A1 (en) 2002-09-27
WO2001019322A3 (en) 2001-10-04
ZA200202060B (en) 2003-05-28
NO20021301D0 (en) 2002-03-15
KR20020032591A (en) 2002-05-03
IL148329A0 (en) 2002-09-12

Similar Documents

Publication Publication Date Title
BR0014041A (en) Use of csaids in rhinovirus infection
BR0316169A (en) Indolyl pyrazinone derivatives useful for treating angiogenesis-associated hyperproliferative disorders and disorders
FR2759581B1 (en) TREATMENT DEVICE, IN PARTICULAR WITH MOXA, OF THE ACUPRESSURE TYPE
TR200002759T2 (en) Cabergoline use in the treatment of leg numbness syndrome.
TR199800815A2 (en) S�lfonilaminokarbonasitler.
ES2248356T3 (en) COMPOUNDS TO TREAT ALZHEIMER'S DISEASE.
SE9703693D0 (en) Novel combination
BR0116323A (en) Heterocyclylazole and -azaindazole compounds as 5-hydroxytryptamine-6 ligands
MY124091A (en) Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
IT1261949B (en) THERAPEUTIC COMPOSITION BASED ON HUMAN INTERFERONE, USE OF HUMAN INTERFERONE IN SUCH COMPOSITION AND RELATED METHOD.
BR0212374A (en) Oxintomodulin for the prevention or treatment of overweight
DK0804437T3 (en) [a] -Assolved pyrrole derivatives and their use in pharmacy
AR025964A1 (en) NASAL TOPICAL TREATMENT
KR960700059A (en) APPLICATION OF CARBAMAZEPINE AND OXCARBAZEPINE IN THE TREATMENT OF PARKINSON'S DISEASE AND PARKINSONIAN SYNDROMES)
DK0755249T3 (en) Use of Maillard reaction inhibitor to treat amyloidosis-based disease
BRPI0412265A (en) use of calcitonin in osteoarthritis
BR9807523A (en) Quinoxalins in triple combination with protease inhibitors and reverse transcriptase inhibitors as drugs for the treatment of AIDS.
BR0113644A (en) Uses of pde5 inhibitor in the treatment of migraine
ATE439363T1 (en) IMIDAZO 2,1-B -1,3,4-THIADIAZOLE SULFONAMIDES
BR0112547A (en) Process for finding compounds that are suitable for obesity treatment and / or prophylaxis
BR0205812A (en) Benzimidazoles Useful in the Treatment of Sexual Dysfunction
SE9904674D0 (en) Novel compounds
IT1264965B1 (en) USE OF ALFA 1-BLOCCANTI IN THE TREATMENT OF EARLY EJACULATION
BR9908716A (en) Treatment of sexual dysfunction in certain groups of patients
SE0004101D0 (en) New use

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A, 8A E 9A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2008 DE 30/06/2009.